Operative and postoperative outcomes in patients undergoing robot-assisted precision prostatectomy, n=8 (MPP; IDEAL stage 1/2a)
| OPERATIVE OUTCOMES | |
| Operative time (incision–closure) in minutes; median (IQR) | 173 (143–185) |
| Console time (console start–finish) in minutes; median (IQR) | 134 (108–148) |
| Patients with suprapubic tube at end of procedure; n (%) | 7 (87.5) |
| Estimated blood loss; median (IQR) | 100 (85–200) |
| Volume of prostate tissue left behind in *cm∧3; median (IQR) | 4 (2–7) |
| Complications/adverse outcomes; n (%) | |
| Intraoperative complications | 0 (0) |
| Margin positivity of the remnant tissue on frozen section analysis | 0 (0) |
| Need for conversion to radical prostatectomy | 0 (0) |
| POSTOPERATIVE OUTCOMES | |
| Length of stay in days; median (IQR) | 1 (1–1) |
| Postoperative complications**; n (%) | 0 (0) |
| Hospital readmission in 30 days; n (%) | 0 (0) |
| Pathological analysis; n (%) | |
| Pathological tumor stage; n (%) | |
| pT2a | 3 (37.5) |
| pT2c | 5 (62.5) |
| Highest Gleason score; n (%) | |
| 3+3 | 1 (12.5) |
| 3+4 | 6 (75) |
| 4+3 | 1 (12.5) |
| Lymph-node involvement; n (%) | 0 (0) |
| Nerve sparing on the side of the dominant nodule; n (%) | |
| Veil | 5 (62.5) |
| Standard | 3 (37.5) |
| Surgical margin positivity; n (%) | |
| On the side of the radical dissection | 0 (0) |
| On the side of the precision prostatectomy | 2 (25) |
| PSA at 12 months; median (IQR) | 0.2 (0.1–0.4) |
| Patients with biochemical recurrence per AUA definition; n (%) | 2 (25) |
| Patients with biochemical recurrence per ASTRO criteria; n (%) | 0 (0) |
| Patients undergone additional therapy at latest follow-up (24-30 months); n (%) | 0 (0) |
| Urinary continent at 12 months; n (%) | 8 (100) |
| Sexual health at 12 months; n (%) | |
| Potent at 12 months*** | 8 (100) |
| Using PDE-5 inhibitors | 4 (50) |
| Using intracavernosal injections | 0 (0) |
*n=6 for this data point; **Postoperative complications included need for blood transfusion, DVT/PE, lymphoceles, urinary tract infection or cardiopulmonary events; ***Five out of the eight patients were potent by 1 month (total=62.5%), an additional two were potent by 4 months (total=87.5%), and all were potent by 12 months (100%).
AUA, American Urological Association; DVT, deep vein thrombosis; PE, pulmonary embolism; PSA, prostate-specific antigen.